Pharmacy Times
JANUARY 2, 2025
Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.
Fierce Healthcare
JANUARY 2, 2025
In this month's payer roundup, CVS faces antitrust questions from Congress as the company lays off more workers following a failed Medicaid bid in Kansas, Oscar Health CEO Mark Bertolini has a bold idea to remake health insurance and Johnson & Johnson is suing Express Scripts in a long-running lawsuit.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
JANUARY 2, 2025
A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.
Pharmacy Times
JANUARY 2, 2025
The approval offers patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
JANUARY 2, 2025
The group is concerned about understaffing, retention challenges and low pay. NYC H+H affiliates and the Doctors Council have been negotiating a new contract for 15 months.
Pharmacy Times
JANUARY 2, 2025
Treatment options may include treating the anemia with blood transfusions, androgen therapy, thalidomide, and other medications.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 2, 2025
Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel.
The Checkup by Singlecare
JANUARY 2, 2025
As glucagon-like peptide-1 (GLP-1) receptor agonists continue to surge in popularity, the U.S. Food and Drug Administration approved the second generic in this class of medications: liraglutide (Victoza). This approval follows the generic version of Byetta (another GLP-1) in November. Generic liraglutide is the first once-daily generic GLP-1 injectable approved to treat Type 2 diabetes in patients 10 and older, alongside diet and exercise.
Drug Topics
JANUARY 2, 2025
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the benefits of glucagon and why pharmacists should be able to prescribe it.
pharmaphorum
JANUARY 2, 2025
Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
JANUARY 2, 2025
Jennifer Goldman, PharmD, CDCES, BC-ADM, discusses how putting glucagon kits in public areas and long-term care facilities can help patients with diabetes.
Pharmacy Times
JANUARY 2, 2025
Immunocompromised older adults developed fewer antibodies against RSV following vaccination compared with immunocompetent individuals.
pharmaphorum
JANUARY 2, 2025
The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price
Drug Topics
JANUARY 2, 2025
XG005 from Xgene Pharmaceutical is a novel, non-opioid chemical entity that targets anti-nociceptive and anti-neuropathic pain pathways.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 2, 2025
Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market
STAT
JANUARY 2, 2025
The new year ushered in a final slate of updates to the federal rules for how hospitals have to disclose their prices, and experts are optimistic the changes will make the data more helpful in identifying less expensive providers. The updates are fairly straightforward. The government is requiring hospitals to include additional pieces of data to improve their consistency and make it easier to compare across hospitals.
pharmaphorum
JANUARY 2, 2025
Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug
Pharmacy Times
JANUARY 2, 2025
PQA Health Equity Technical Expert Panel recommendations inform measure testing, use in quality programs, and risk adjustment models
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JANUARY 2, 2025
Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.
Pharmacy Times
JANUARY 2, 2025
The regulatory decision marks a significant step forward in the treatment of non-tuberculous mycobacteria infections.
Pharmaceutical Technology
JANUARY 2, 2025
Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.
Pharmacy Times
JANUARY 2, 2025
The model, Deep-IO, shows improved specificity and sensitivity compared with existing predictive biomarkers.
Pharmaceutical Technology
JANUARY 2, 2025
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
Pharmacy Times
JANUARY 2, 2025
Although each of the product samples of phenibut contained the actual active ingredient, the exact amount of the active ingredient was inaccurate and, in one sample, found to be at a higher dose.
Fierce Healthcare
JANUARY 2, 2025
UnitedHealth Group and Amedisys have pushed back the closure date for their $3.3 billion merger as they fend off a federal challenge to the deal. | UnitedHealth Group and Amedisys have pushed back the closure date for their $3.3 billion merger as they fend off a federal challenge to the deal.
Pharmacy Times
JANUARY 2, 2025
Pharmacists can educate patients on controlling risk factors and stay up-to-date on emerging therapies like SGLT2 inhibitors and finerenone that can slow disease progression.
Fierce Healthcare
JANUARY 2, 2025
NeueHealth, the care management company formerly known as Bright Health, is set to be acquired by venture capital partner New Enterprise Associates later this month. | NeueHealth is getting bought out by an affiliate of New Enterprise Associates, making the company privately held.
Pharmacy Times
JANUARY 2, 2025
The big three PBMs rake in billions from government drug programs while patients pay more and small pharmacies are squeezed out, says NCPA
DiversifyRx
JANUARY 2, 2025
KPI optimization is critical to improving the performance of your independent pharmacy. If you dont measure it, you cant improve itthis statement has never been truer for pharmacy owners. Key Performance Indicators (KPIs) are the benchmarks of success, providing insights into your pharmacys performance and guiding smarter decisions. Yet, many pharmacy owners overlook this critical aspect, focusing on day-to-day operations without a clear picture of their businesss health.
Pharmacy Times
JANUARY 2, 2025
Congress fumbled a chance to rein in big insurance and PBMs and save taxpayers billions, says NCPA
Pharmaceutical Technology
JANUARY 2, 2025
Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable industry insights.
Pharmacy Times
JANUARY 2, 2025
Dicyclomine Hydrochloride Capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome.
Pharmaceutical Technology
JANUARY 2, 2025
The Phase III KOASTAL-1 study with Neumoras lead asset navacaprant failed to meet its primary and secondary endpoint.
Expert insights. Personalized for you.
145 
Let's personalize your content